CAMBRIDGE, Mass. and SAN FRANCISCO, Dec. 16, 2021 (GLOBE NEWSWIRE) -- Cerevel Therapeutics (Nasdaq: CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, and Herophilus, a leading biotechnology company developing neurotherapeutics to cure complex brain diseases, today announced a phased multi-year, joint research collaboration in neuropsychiatry. The collaboration integrates the deep expertise in neuroscience drug discovery at Cerevel Therapeutics with state-of-the-art disease models and the AI-enabled deep phenotyping from Herophilus.
Read more at globenewswire.comProvided Content: Content provided by Globe Newswire. The Globe and Mail was not involved, and material was not reviewed prior to publication.